In 2021, with high‐level evidence, BC clinical practice guidelines2, 3 continued to recommend trastuzumab or trastuzumab + pertuzumab combination chemotherapy regimens as neoadjuvant/adjuvant therapy for HER2‐positive BC patients with indications. Here, ERBB2 is linked to breast cancer.